DURECT Corp (NASDAQ:DRRX)

1.13
Delayed Data
As of Feb 23
 +0.01 / +0.89%
Today’s Change
0.74
Today|||52-Week Range
2.17
+22.59%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$167.9M

Company Description

DURECT Corp. engages in the research and development of therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Contact Information

DURECT Corp.
10260 Bubb Road
Cupertino California 95014-4166
P:(408) 777-1417
Investor Relations:
(408) 777-4936

Employees

Shareholders

Other institutional34.27%
Individual stakeholders21.89%
Mutual fund holders10.63%

Top Executives

James E. BrownPresident, Chief Executive Officer & Director
Judy JoiceSenior VP-Operations & Corporate Quality Assurance
Matt HoganCFO, Secretary & Principal Accounting Officer
Steve HelmerChief Patent Counsel & Vice President
Su Il YumEVP-Pharmaceutical Systems Research & Development